Treatment-Related Toxicity: Phase II Trial for Older/Frail Stage III NSCLC Patients

56 patient records from a phase II randomized trial investigating reduced radiotherapy intensity for older or frail patients with stage III non-small-cell lung cancer. The dataset includes 1-year progression-free survival rates, objective response rates, overall survival, and safety outcomes, including grade 3/4 adverse events. The trial was conducted at a tertiary hospital in China between September 2022 and April 2024.

Use Cases

• Compare survival outcomes based on radiotherapy intensity for patients intolerant to concurrent chemoradiotherapy.
• Analyze the incidence and severity of adverse events associated with different treatment regimens.
• Model the feasibility of reduced radiotherapy combined with sequential chemo-immunotherapy for frail patient populations.

Strengths

• Data originates from a registered, randomized phase II clinical trial (NCT05557552).
• Includes detailed safety analysis with reported rates of grade 3/4 and grade 5 adverse events.
• Provides Kaplan-Meier estimates for 1-year progression-free survival with 95% confidence intervals.

Limitations

• The trial had a non-comparative design and a small sample size of 56 patients.
• The description notes a lack of statistical power to establish non-inferiority or superiority.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

Wei-Xiang Qi via figshare.

Collection Method

Data collected from a phase II randomized, open-label, two-cohort clinical trial.

Time Range

Patient enrollment between September 30, 2022 and April 30, 2024, with a median follow-up of 24 months.

Freshness

Last updated 2026-05-27 18:00:16; freshness should be verified.

Geography

Trial conducted at a tertiary hospital in China.